BraiN20®: A paradigm shift in Acute Ischemic Stroke (AIS) patient management
Acute Ischemic Stroke (AIS) represents 85% of strokes and is the 2nd leading cause of death and the leading cause of disability worldwide. Today, AIS patient management lies on imaging tools (multimodal CT/MRI) and scores to selec...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
VThrombectomy
Improving Treatment of Ischemic Stroke Using Virtual Thrombe...
189K€
Cerrado
LVOCheck
Diagnosis of large vessel occlusion (LVO) in acute stroke fo...
4M€
Cerrado
NIMBLE System
"The NIMBLE System: A novel non-invasive and non-ionizing me...
3M€
Cerrado
NIMBLE WOMENTECHEU
A novel non-invasive and non-ionizing medical device for mon...
75K€
Cerrado
TED2021-131201B-I00
DIAGNOSTICO DIGITAL: TRANSFORMACION DE LA DETECCION DE ENFER...
222K€
Cerrado
StrokeMonitor
Monitoring of stroke patients with 3D ultrasound localizatio...
150K€
Cerrado
Información proyecto promise
Duración del proyecto: 36 meses
Fecha Inicio: 2023-04-05
Fecha Fin: 2026-04-30
Líder del proyecto
TIME IS BRAIN SL
Investigacion, desarrollo, innovacion, consultoria, produccion, fabricacion, comercializacion, explotacion, distribucion, importacion y expo...
TRL
3-4
| 125K€
Presupuesto del proyecto
5M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Acute Ischemic Stroke (AIS) represents 85% of strokes and is the 2nd leading cause of death and the leading cause of disability worldwide. Today, AIS patient management lies on imaging tools (multimodal CT/MRI) and scores to select patients for Endovascular treatment (EVT) – the gold standard. Still, its efficacy is limited to 46% due to the lack of tools to guide decision-making. BraiN20® is a non-invasive medical device class IIb that provides real-time monitoring of AIS patients’ brain viability, thereby predicting who will benefit from EVT. Time is Brain has the exclusive right to the IPR of a neurophysiological biomarker: N20, a SEP and surrogate of cerebral blood flow. TiB aims to implement the clinical trials to validate BraiN20®, acquire CE-Mark and FDA clearance, and bring it to market. By providing real-time and continuous monitoring of brain viability, BraiN20® will accelerate stroke management and predict EVT outcome and offer tailored care for each patient.